

# Global Leader in Relapsed/Refractory AL Amyloidosis

ASH

This presentation contains clinical data  
presented at ASH Dec 7, 2025  
on pages 28 - 32

January 2026





## Disclaimer: Forward Looking Statements & Market Data



This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.'s (the "Company") strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation.

The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. This presentation also includes data from other approved therapies and in trials, which are generated from separate, independent studies and do not come from head-to-head analysis. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies sourced from publicly available sources. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.



The Moment Every Doctor and Family Dreads...

*"There's Nothing More We Can Do."*

In cases of relapsed/refractory AL amyloidosis,  
that sentence is delivered to ~38,500 patients in the U.S.


It's not good enough  
to accept the status quo

*I've been the doctor in that room.  
I've watched hope disappear,  
and I couldn't accept that months  
of suffering and subsequent  
death was "standard of care."*



Ilya Rachman, MD PhD, Founder and CEO






## When Your Immune System Becomes Your Killer

*Normally, antibodies protect us like superheroes.  
In AL amyloidosis, they go rogue, turning into supervillains that flood organs with toxic light chains.*




# Painful and Unnecessary Months of Suffering

Healthy




AL Amyloidosis



These toxic light chains clog up the heart, kidneys, and liver. Breathing becomes difficult, swelling begins, and even a short walk becomes challenging.

# AL Amyloidosis: ~38,500 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs

NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE




Source: Merlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Hemato 2022, 3(1), 47-62. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMCID: PMC5965052. Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.



# The Current Paradigm is Failing: Standards of Care

12 PATIENT SERIES RELAPSED/REFRACTORY AL AMYLOIDOSIS RECEIVING SECOND LINE THERAPY



**There are no drugs approved in relapsed/refractory AL amyloidosis.**  
**Current investigators' choice agents produce an unsatisfactory reduction in AL amyloidosis disease markers (dFLC) with a low (0-10%) complete response (CR) rate**

# The Toxic Current Last-Ditch Effort

Only one 4-drug combination is approved for newly diagnosed patients only. Once relapse hits, there's nothing FDA approved. Doctors often resort to off label drug uses, despite their limited efficacy.



*We're developing a breakthrough with the goal of changing that hopeless sentence*

Our mission is simple:  
Create medicines that work without destroying the patient.

# The Science That Enables Our Platform

NXC-201 sterically-optimized CAR-T's "Digital Filter" ....reduces non-specific activation



1

**Proprietary Optimized CD3 – “CD3ζγ”**  
✓ Delivers “Digital” Intracellular Signaling

NXC-201 CAR-T

CD3ζγ

4-1BB

2

**Proprietary Optimized CD8 Hinge Flexibility**  
✓ Reduces cytokine release

Sterically-optimized key construct modifications

CD8 Transmembrane Protein

CD8 Hinge

3

**Proprietary Optimized COBRA Binder**  
✓ Enhances Plasma Cell Binding  
✓ Enables High Expression

COBRA Binder

CD8 Signaling Protein



# Extraordinary Results in Clinical Trials


## Relapsed/refractory AL Amyloidosis - Market Situation

Current Standards of Care



0-10% complete response rate  
(standard of care)

NXC-201



75% complete response rate  
(ASH 2025)

What that can mean for the patient...

Life becomes normal again.

A deep breath that reaches the bottom of the lungs.  
A walk that doesn't end at the mailbox.  
A normal heartbeat again.



# The Multi-Billion Dollar Economic Scale of This Impact



**~38,500 patients**

**~\$422K**

Existing reimbursement for  
BCMA CAR-T

**MULTI-BILLION-DOLLAR MARKET**

# Our Unique Position to Transform This Disease

No approved therapies for relapsed/refractory patients.  
RMAT + Orphan Drug Designation were granted to us in February 2025 and September 2023, respectively




# The Road Ahead



## Prior

- ✓ Secured rights to NXC-201, N-GENIUS platform
- ✓ FDA Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) Designation Granted
- ✓ Mentioned in New England Journal of Medicine (NEJM) AL Amyloidosis Review
- ✓ Reported ex-U.S. NEXICART-1 AL Amyloidosis data at ASGCT 2023, ASH 2023, ASGCT 2024, ASH 2024, JCO published 2024
- ✓ NEXICART-2 U.S. AL Amyloidosis clinical trial first 6 patients dosed; first patient at Memorial Sloan Kettering Cancer Center (met guidance)
- ✓ Reported first 4 patients U.S. NEXICART-2 AL Amyloidosis clinical data 4Q 2024 (met guidance)
- ✓ Reported first 10 patients U.S. NEXICART-2 AL Amyloidosis clinical data Q2 2025 at ASCO 2025



# The Road Ahead

**>50% enrolled**

**BLA submission for  
approval planned  
2/3Q 2026**



# The Road Ahead: Commercial

**18 high-prescribing  
Sites in existing Immix  
clinical trial**

**Commercial launch  
plan late 2026/early  
2027<sup>1</sup>**


1) Assuming BLA submission 2/3Q 2026 and subsequent BLA approval

# We believe that NXC-201 has the potential to treat a number of diseases beyond AL

CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body)



## AL Amyloidosis



Infiltrates and damages heart

## Neurology



- Myasthenia Gravis
- NMO Spectrum Disorder

## Hematology



- Thrombotic thrombocytopenic purpura
- Immune Thrombocytopenia

## Rheumatology



- Systemic Lupus Erythematosus
- Rheumatoid Arthritis

## Vascular



- ANCA vasculitis

Disease-causing antibodies

AL amyloid antibody deposits

Light chain antibody fragments



**ANTIBODY FACTORY PLASMA CELL**  
(NXC-201 therapeutic target)

Note: select indications noted above are for illustrative purposes only.

\*Illustrative list of immune-mediated diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment

Source: MedicTests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non randomised phase 1/2a study. Lancet Neurol. 2023. McGlothlin J, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Front Immunol. 2023. Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol. 2019



# A World Class Team Dedicated To Saving Lives



Ilya Rachman, MD, PhD  
Chief Executive Office



David Marks, MBBS, PhD  
Chief Medical Officer



Gabriel Morris  
Chief Financial Officer



Amanda Squires  
Head of Clinical Operations



Michael Grabow  
Chief Commercial Officer



Oleg Evgrafov,  
Head of Quality



Denise Bruns Senior  
Regulatory Advisor



Mel Davis-Pickett,  
Head of Technical Development





We believe we are on the brink of turning despair into hope

Success here opens the door to treating additional immune diseases



We endeavor to change the sentence forever...

"Are there any options left?"  
Because of Immix, the answer is:  
"Yes."


# NEXICART-1: Single-Center Ex-US CAR-T NXC-201 Clinical Trial





# NEXICART-1 (Israel): Normalization of Diseased Free Light Chains 30 Days after Dosing

NXC-201 RAPIDLY ELIMINATED DISEASED AL AMYLOIDOSIS PLASMA CELLS WITHIN ~30 DAYS



“An early and deep hematologic response has been found to lead to significantly prolonged survival”

– *Vaishali Sanchorawala, M.D.*  
Professor, Hematology and Oncology  
Director, Amyloidosis Center at Boston University School of Medicine  
Director, Stem Cell Transplantation at Boston Medical center

doi: 10.1056/NEJMra2304088

**NXC-201**  
**75% complete response rate**  
**(NEXICART-1)**

**Current investigator’s choice therapies**  
**0-10% complete response rate**  
**No FDA Drugs approved**

Note: Data cut-off as of December 9, 2024. As presented in Journal of Clinical Oncology. Patient 13 included in 75% complete response (CR) rate, but not included in graph above.  
Source: E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024.



# NEXICART-2: Multi-Center U.S. CAR-T NXC-201 Clinical Trial with Registrational Design

**ASH**

**Presented Dec 7, 2025 at ASH**



# NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)

U.S. TRIAL WITH REGISTRATIONAL DESIGN ONGOING



## Study design

- Open-label, single-arm, multi-site phase 1/2 study
- n=40 patients

## Key criteria

Inclusion	•AL Amyloidosis patients exposed to at least 1 line of therapy including a CD38 monoclonal antibody
Exclusion	•Prior anti-BCMA directed therapy •Cardiac: Mayo stage 3b, NYHA stage III/IV •Concomitant Multiple Myeloma

## Outcome measures

- Safety
- Efficacy: Complete hematologic response (CR) based on validated criteria (normalized light chains and negative immunofixation)

Note: Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012. "Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis." Leukemia 26(11): 2317-2325.)



# NEXICART-2 (U.S.) Baseline Characteristics: Representative of U.S. R/R AL Amyloidosis Patient Population



ASH  
Presented Dec 7, 2025 at ASH

 preserved heart function

	NX2-001	NX2-002	NX2-003	NX2-004	NX2-005	NX2-006	NX2-007	NX2-008	NX2-009	NX2-010	NX2-011	NX2-012	NX2-013	NX2-014	NX2-015	NX2-016	NX2-017	NX2-018	NX2-019	NX2-020	Median (range)
Age	56	67	82	64	62	72	77	66	63	80	65	65	59	49	73	59	71	71	82	64	66 (49-82)
Gender	Female	Female	Male	Female	Female	Male	Male	Male	Male	Male	Female	Female	Female	Female	Female	Male	Male	Female	Female	Female	-
Prior lines of therapy	4^	6^^	2	4	4^	3	4^	4^	4^	3^	1	10	4^^	1	8^	5	2	9^	2	3^	4 (1-10)
Follow-up (days)	505	477	421	393	127	330	302	295	287	245	238	232	90	210	203	182	169	147	147	140	235 (90-505)
dFLC (mg/L)	65	24	-	86	42	26	47	121	84	-	-	70	274	26	54	24	194	73	45	22	54 (22-274)
M-Spike (g/dL, if dFLC not inclusion criteria)	-	-	0.79	-	-	-	-	-	-	0.65	0.52	-	-	-	-	-	-	-	-	-	-
Organ involvement	Heart/ Soft Tissue	Heart/GI/ Nerve	Kidney	Heart/ GI/Nerve	Kidney	Heart	Nerve/ Skin	Heart/ Liver	Heart/ Tongue	Kidney/ Heart	Heart/ Nerve/GI	Heart/GI	Heart	Heart/GI/ Nerve	Kidney	Nerve	Heart/ Kidney	Kidney	GI	Kidney	-
NYHA stage	I	II	I	I	I	I	I	II	I	II	II	II	I	II	I	I	II	I	I	I	-
NT-ProBNP (ng/L)	146	560	1,297	218	805	989	143	909	289	290	2,017	232	155	355	1,385	113	627	526	231	NA	355 (113-2,017)
hs-Troponin-I (ng/L)	7	6	42	7	11	31	14 <sup>†</sup>	47*	6	52	6	11 <sup>†</sup>	13	10*	8	14*	75*	7	5	0	10 (0-75)
Creatinine (mg/dL)	0.7	1.1	2.2	0.7	2.7	0.8	1.3	0.8	0.9	0.9	0.5	1.0	0.9	0.6	1.3	1.0	1.0	0.7	0.8	1.2	0.9 (0.5-2.7)
Albuminuria (mg/24 hrs)	143	0	3,032	0	10,274	0	135	360	13	2,153	135	144	136	310	2,061	6	5,660	2,000	140	4,478	144 (0-10,274)
Mayo Stage at Diagnosis	II	II	II	IIIa	I	IIIa	-	II	IIIb	IIIa	II	I	IIIa	II	II	I	IIIa	I	I	I	-
Mayo Stage at Enrollment	I	II	IIIa	IIIa	II	IIIa	-	II	I	II	II	I	II	I	II	I	IIIa	II	I	I	-



^ Prior autologous stem cell transplantation (ASCT)  
^^ Two prior ASCT  
\*Denotes hs-Troponin-T; † Denotes Troponin-T  
Note: Data cut-off as of November 13, 2025




NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains (FDA Endpoint) within ~First Month



ASH  
Presented Dec 7, 2025 at ASH



Organ responses in 70% (7/10) evaluable patients (75% ❤️, 60% 🧡, 100% 🟢)



Subject #	NX2-013	NX2-016	NX2-007	NX2-017	NX2-001	NX2-002	NX2-004	NX2-005	NX2-006	NX2-008	NX2-009	NX2-010	NX2-011	NX2-012	NX2-014	NX2-015	NX2-018	NX2-019	NX2-020
Time to response (days)	7	7	7	7	14	7	7	7	7	7	7	7	7	7	7	7	160	7	15
Disease Marker status as of data cutoff	Above Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
Follow-up(days)	90	182	302	169	505	477	393	127	330	295	287	232	210	203	147	147	140	238	245

Note: Data cut-off as of November 13, 2025. dFLC: difference in free light chain (disease marker). Renal response based on AL Amyloidosis consensus criteria for renal response (Palladini G et al 2014 doi: 10.1182/blood-2014-04-570010). Most recent available dFLC reading for patient NX2-001 as of day 448. For patient NX2-002, as of day 446. 3 out of 4 cardiac organ responses evaluable – NX2-006, NX2-008, NX2-011, NX2-015. 3 out of 5 renal responses evaluable – NX2-003, NX2-010, NX2-015, NX2-017, NX2-020. 1 out of 1 liver response evaluable – NX2-008. AL Amyloidosis disease markers on line graph: All patient data is dFLC (left-hand side vertical axis), except for patients NX2-003, NX2-010, and NX2-011 which are m-spike (right-hand side vertical axis). Patient NX2-013 withdrawn from study on D+90 days due to hematologic progression. NX2-011 M-spike igg type (longer half-life) NX2-003, NX2-010 M-spike iga type (shorter half-life).


# NEXICART-2 (U.S.) Clinical Activity: 75% Complete Responses (CR) – 15/20 Patients; Additional Four Patients Disease Markers Normal, Predicting Future CR



Subject #	NX2-001	NX2-002	NX2-003	NX2-004	NX2-005	NX2-006	NX2-007	NX2-008	NX2-009	NX2-010	NX2-011	NX2-012	NX2-013	NX2-014	NX2-015	NX2-016	NX2-017	NX2-018	NX2-019	NX2-020
Time to response (days)	14	7	15	7	7	7	7	7	7	7	160	7	7	7	7	7	7	7	7	7
Hematologic response	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	Pending (M-Spike Normal) Already MRD (-) 10 <sup>-5/6</sup>	Pending (Light Chains Normal) Already MRD (-) 10 <sup>-5/6</sup>	Withdrawn	CR	CR	Pending (Light Chains Normal) Already MRD (-) 10 <sup>-5/6</sup>	CR	CR	Pending (Light Chains Normal) Already MRD (-) 10 <sup>-5/6</sup>	CR

Complete response (CR) is FDA  
Regulatory Endpoint

ASH  
Presented Dec 7, 2025 at ASH



Existing investigator's choice therapies  
0-10% complete response rate  
No FDA Drugs approved

- Organ responses in 70% (7/10) evaluable patients (75% ❤️, 60% 🧡, 100% 🧡)

Note: Data cut-off as of November 13, 2025. Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012. "Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis." Leukemia 26(11): 2317-2325.) Patients NX2-003, NX2-010, and NX2-011 enrolled on M-Spike. NX2-011 M-spike igg type (longer half-life) NX2-003, NX2-010 M-spike iga type (shorter half-life). Source: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Additionally, Patients NX2-011, NX2-012, NX2-016, NX2-019 MRD negative in bone marrow by flow cytometry (10<sup>-6</sup> sensitivity) or clonoSEQ (10<sup>-6</sup> sensitivity).

# NEXICART-2 (U.S.) Safety: Consistent or Improved Compared to Ex-US Dataset



- No ICANS neurotoxicity of any kind
- Grade 2 CRS in four patients, Grade 1 CRS in 11 patients, median 1-day duration

ASH

Presented Dec 7, 2025 at ASH

Subject		NX2-001	NX2-002	NX2-003	NX2-004	NX2-005	NX2-006	NX2-007	NX2-008	NX2-009	NX2-010	NX2-011	NX2-012	NX2-013	NX2-014	NX2-015	NX2-016	NX2-017	NX2-018	NX2-019	NX2-020
Dose	CART Cell Dose (x10 <sup>6</sup> )	150	150	150	450	450	450	450	450	450	450	450	450	450	450	450	450	450	450	450	450
Key	Neurotoxicity	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
	Cytokine release syndrome (CRS)	None	None	Grade 2	Grade 1	Grade 1	Grade 1	Grade 1	Grade 1	Grade 1	Grade 1	Grade 2	Grade 1	None	Grade 2	Grade 2	None	Grade 1	Grade 1	Grade 1	None
	CRS Onset (days)	None	None	3	3	1	1	1	1	1	3	2	1	None	1	1	None	1	1	2	None
	CRS Duration (days)	None	None	2	1	1	1	1	4	1	2	1	5	None	1	2	None	1	1	1	None
Other	Neutropenia	Grade 3	Grade 3	Grade 3	Grade 4	Grade 4	Grade 2	Grade 4	Grade 4	Grade 4	Grade 2	Grade 4	Grade 4	Grade 4	Grade 4	Grade 3	Grade 3	Grade 3	Grade 3	Grade 3	None
	Febrile Neutropenia	None	None	None	None	None	None	None	Grade 3	None	None	None	None	None	None	None	None	None	None	None	None
	Anemia	Grade 1	Grade 2	Grade 3	Grade 1	Grade 3	Grade 1	Grade 2	Grade 2	Grade 1	Grade 1	Grade 2	Grade 2	Grade 1	Grade 3	Grade 3	Grade 1	Grade 2	Grade 2	Grade 3	Grade 3
	Thrombocytopenia	Grade 1	Grade 1	Grade 1	Grade 1	Grade 3	Grade 2	None	Grade 4	Grade 3	Grade 1	Grade 1	Grade 3	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 1	Grade 1	None
	Acute kidney failure	None	None	None	None	Grade 4 acute on chronic kidney injury (pre-existing stage 4 chronic kidney disease at enrollment)	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
	LFT Abnormalities	None	None	None	None	None	None	None	Grade 1	None	None	None	Grade 3	None	Grade 3	None	None	Grade 1	None	None	None
	≥ Grade 3 Infections	None	None	None	None	Grade 5*	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None
	Fatigue	None	Grade 2	Grade 2	Grade 2	Grade 1	Grade 1	None	None	None	Grade 2	Grade 2	None	Grade 2	None	Grade 2	Grade 2	None	None	None	None
	Cardiac Event	None	None	None	Grade 2**	None	None	None	None	None	Grade 2**	None	None	None	None	None	None	None	None	None	None

\*Event unrelated to NXC-201; acute on chronic kidney injury in patient with stage 4 CKD at enrollment  
\*\*Two patients with pre-existing atrial fibrillation experienced transient arrhythmias responsive to beta-blockers  
Note: Data cut-off as of November 13, 2025. CRS and ICANS reported according to ASTCT Consensus Grading (Lee et al. 2019). Patient NX2-013 withdrawn on day 90.



# Complete Response Rate Improving Over Time

ASH


Presented Dec 7, 2025 at ASH



Data Cutoff April 11, 2025

ASCO®

70% CR RATE



Data Cutoff November 13, 2025

ASH

100% CR RATE

Subject #	NX2-001	NX2-002	NX2-003	NX2-004	NX2-005	NX2-006	NX2-007	NX2-008	NX2-009	NX2-010
Time to normalization (days)	14	7	15	7	7	7	7	7	7	7
Hematologic response	CR	CR	CR	Pending (already MRD (-)10 <sup>-6</sup> )	CR	CR	Pending (already MRD (-)10 <sup>-6</sup> )	CR	Pending (already MRD (-)10 <sup>-6</sup> )	CR

Subject #	NX2-001	NX2-002	NX2-003	NX2-004	NX2-005	NX2-006	NX2-007	NX2-008	NX2-009	NX2-010
Time to normalization (days)	14	7	15	7	7	7	7	7	7	7
Hematologic response	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR

# Global Leader in relapsed/refractory AL Amyloidosis

January 2026






# NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population



## Prevalence: Relapsed/Refractory (“R/R”)

## Incidence: Newly Diagnosed / Front Line



## Blue Ocean Opportunity

- 0-10% complete response rate for existing therapies in R/R AL
- No FDA Approved Drugs in Relapsed / Refractory AL Amyloidosis

## Therapies



Front-line  
only

Approved




(Darzalex combined with cyclophosphamide, bortezomib, and/or dexamethasone)

Source: Mayo staging: 1) Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. ASCT: 2) Bomsztyk J et al, Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective. Expert Review of Hematology 2022. 3) Gustine J et al, Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. AJH 2022. Incidence and prevalence: 4) According to Amyloidosis Foundation. Accessed 11/30/2025. 5) Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Incidence growth rate: 6) Laires P et al, Prevalence, Incidence, and Characterization of LIGHT Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records (EHR). Blood 2023. Daratumumab: 7) Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. 8) Chakraborty R et al, Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study. AJH 2024. 9) Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115.



# Expected Annual U.S. NXC-201 Patient Dosing: R/R AL Amyloidosis

NXC-201 TARGET PATIENTS RECENTLY RELAPSED WITH ADEQUATE HEART/KIDNEY FUNCTION



Note: Site numbers are illustrative; based on Company calculations taking into account number of patients with long-term remission from NXC-201 treatment and annual deaths due to AL Amyloidosis  
Source: Management estimates, prevalence: Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Mayo staging: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. End stage renal: Shafqat A, et al. Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management. J Clin Med 2024. NYHA Class: Bazarbachi A, et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. American Journal of Hematology 2024. Laires P et al, Prevalence, Incidence, and Characterization of LIGHT Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records (EHR). Blood 2023

# NXC-201 Tolerability Drives AL Amyloidosis Leadership


ALL BCMA CAR-TS ARE NOT CREATED EQUAL



NXC-201’s short CRS duration makes it **uniquely suitable to treat ALA patients** (in whom the #1 source of mortality is heart failure)

Cardiovascular stress is the key determinant for ability to treat relapsed/refractory ALA patients

- Long CRS duration causes extended cardiovascular stress
- Other CARTs have 4-8x longer CRS duration



“The biggest challenge ... has been applicability of these therapies in amyloidosis **when the patients are particularly frail and have organ dysfunction** ... where the key lies in the safety rather the efficacy in a low-volume disease setting is going to be key ... ”

– Dr. Susan Bal, MD  
Assistant Professor, Hematology  
University of Alabama at Birmingham

Median CRS Duration (Days)



Source: M. Assayag, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Poster Presentation. April 2023. Nov 2023 KOL discussion;NXC-201 (formerly HBI0101) American Society of Hematology Presentation, Abecma FDA approval label, Carvykti FDA approval label, Arcellx S-1. NXC-201 data from NEXICART-1 clinical study. L. Lee, et al. Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence. ASH 2023. Studies not head-to-head  
Note: FDA label information sourced from initial labels post approval


Data in Multiple Myeloma

# NXC-201 Advantage: Overcoming Neurotoxicity<sup>1</sup>


ALL BCMA CAR-TS ARE NOT CREATED EQUAL



## LOW VOLUME DISEASE



## HIGH VOLUME DISEASE



Source: Carvykti and Abecma FDA labels, Arcellx S-1. Assayag, et al. Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024 Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023.

Note: FDA label information sourced from initial labels post approval

1) Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Figures reflect cross-trial comparison and not results from a head-to head study. Kyverna corporate presentation June 14, 2024.

2) Low volume diseases refers to ANCA vasculitis, autoimmune encephalitis, anti-synthetase syndrome, CIDP, DAGLA encephalitis, IgG4 related disease, Lambert-Eaton myasthenic syndrome, lupus nephritis, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic sclerosis, Stiff Person syndrome Cabaletta 2Q 2024 earnings press release. High volume disease NXC-201 CRS data from ASH 2024 Abstract which included 84 MM patients. NXC-201 data from NEXICART-1 clinical study.



NXC-201: 1 Deepest Responses, 2 In Most Heavily Pretreated Population




		NXC-201	Etentamig	Teclistamab
NXC-201: Later Phase ...	n	20	34	17
	Phase	Phase 2	Phase 1	Retrospective
... in heavily pre-treated population ...	Median Prior Lines	4	2	4
	Prior ASCT ?	55%	21%	NA
... with independent review committee (IRC) adjudicated responses ...	Complete Response Rate	75% (potential future: 95%)(1)	82%	41%
	Independent Review Committee (IRC)?	✓ Yes(2)	✗ No(3)	No
... faster, deeper, and more frequent downstream organ responses	Cardiac Organ Response	75%	39%	25%
	Median Time to Cardiac Response	1.1 Months	2.1 Months	NA
	Renal Response	60%	54%	10%
	ICANS	0%	0%	6% (All Grade 3)
	Infections (≥Grade 3)	0%	3%	29% (Including Grade 5)
	IVIg Prophylaxis	NA	91%(4)	NA
	Dosing Frequency	1-Time	24 Months (QW4)	Weekly (Median time on therapy: ~4.5 months)

# NXC-201: Deepest Responses...




Complete Response Rate



- Despite the more difficult patient population, Immix saw **similar complete response rates**
- **Immix CR rate has potential to evolve up to 95% with 4 non-CR patients MRD negative**
- **Immix CR rates adjudicated by IRC vs AbbVie results which are investigator assessed**

Organ Response




- Immix had **higher organ responses**

2

# ... In Most Heavily Pretreated Population




Prior Lines of Therapy




- Immix enrolled a **more refractory patient population**

Prior ASCT



- **Significantly more NXC-201 patients had prior stem cell transplants**

Dosing Regimen




- Immix provides a **one-and-done therapy** vs a 24-month therapy

Source: Company Public Filings  
Note: All data from ASH December 2025




# Market Reference: Commercialization Cost Trend Over Time



Source: Company Materials, Wall Street Research  
Note: \$ in millions; (1) Calculated as COGS and SG&A in launch year; (2) Represents COGS of Carvykti shared between J&J and Legend (50/50 profit share) and Legend SG&A multiplied by 2 to more closely reflect total costs; (3) Represents total costs for Casgevy between CRISPR and Vertex; (4) Represents total costs for Roctavian, disclosed as R&D + SG&A

100% of doses manufactured successfully, median vein-to-vein time of 14 days



# Building the National Treatment Infrastructure






AL Amyloidosis – an active, multi-billion dollar indication

Annual sales into AL Amyloidosis

\$1.7 billion<sup>1</sup>+



Acquisition



Company



Source: Company, Pitchbook, Public information  
1) (4,500 new cases AL) / (SEER New Cases MM in 2025 36,110) = 12.4% \* \$14bn annual run rate = \$1.7bn

# Appendix

January 2026





# Superior FDA Approval Rate for Drugs with Breakthrough Designations

Jefferies

USA | Biotechnology

Thematic  
Research

Equity Research  
October 5, 2025

## 70%+ FDA Approval Rate for Drugs w/ Breakthrough Designations - AXSM, DYN, AKRO

We calculate a high 72% US approval rate for drugs that received breakthrough designations (**BTDs**) between 2013-2022 (N=338/467), with another 13% still pending. Our discovery suggests BTD drugs may command a higher PoS than Street expectations (particularly if their data is debated). Our stocks with BTD drugs in the pipeline include **AXSM** (Alz agitation), **SVRA** (aPAP), **AKRO** (MASH), **BIIB** (felzartamab), **DYN** (DM1/DMD), **DNLI** (Hunter), **STOK** (Dravet), **PRAX** (SCN2A/8A).

**\*\* See inside for key charts & tables\*\***


**Big Picture:** We remain (+) on the state of the FDA, even after Dr. Peter Marks' CBER resignation (March 2025) and Dr. Vinay Prasad's subsequent appointment (May 2025), departure (July 2025), and return (Aug 2025). Our work on 2025 AdComs, approvals and CRLs, as well as commentary from 375+ SMID-caps and Big Pharma, leads us to think the regulatory environment has not worsened (vs prior years). The FDA has introduced a new pathway for ultra-rare diseases, and it will share a list of 10-12 drugs that qualify for expedited CNPV in the coming weeks. Meanwhile, our new analysis of 599 breakthrough designations (**BTDs**) from 2013 to 2025 YTD provides another pot'l proofpoint that the "new FDA" remains functional. Our data can also help the Street better handicap regulatory events across the industry.

Exhibit 10 - 10-year (2013-2022) Approval Success Rate For Assets Granted BTDs is 72%



Source: Jefferies; FDA; Friends of Cancer Research; Biomedtracker

Exhibit 11 - Assets Granted BTDs Within Oncology and Autoimmune/Immunology Indications From 2013-2022 Saw 79%+ Approval Rates



\*Non-Malignant Hematology




# Numerous Successful Launches Contributed to Strong Equity Performance

RECENT MAJOR COMMERCIAL LAUNCHES HAVE EXCEEDED INITIAL EXPECTATIONS; YEAR 10 STREET CONSENSUS REVENUE ESTIMATES HAVE INCREASED CONSIDERABLY OVER TIME IN MOST CASES



Year 10 Sales Estimates at Approval vs. Current for 2024-2025 Product Launches (\$B)



Source: Visible Alpha; market data as of 01/08/2026

1) Defined as first full year post launch

2) Time of approval and launch year relates to Amvuttra in ATTR-CM

3) Sales in ATTR-CM not broken out

4) Current Year 10 estimates as of Merck’s acquisition announcement of Verona (07/09/2025)

# Global Leader in Relapsed/Refractory AL Amyloidosis

ASH

This presentation contains clinical data  
presented at ASH Dec 7, 2025  
on pages 28 - 32

January 2026

